Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Core Insights - Seres Therapeutics, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, focusing on its biotherapeutics pipeline and specifically on SER-155 [1][2] Company Overview - Seres Therapeutics is a clinical-stage company specializing in live biotherapeutics aimed at improving outcomes for medically vulnerable populations [3] - The company successfully developed VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [3] Product Development - SER-155 has received Breakthrough Therapy designation from the FDA for reducing bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant [2] - Clinical study results indicated a 77% relative risk reduction in BSIs associated with SER-155, along with a significant decrease in systemic antibiotic exposure and lower incidence of febrile neutropenia [2] - The company is exploring partnerships to enhance the development of SER-155 and other pipeline candidates for various medically vulnerable populations [2][3] Target Populations - SER-155 is intended for use in multiple patient groups, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care units [2][3]